|
1
|
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
|
N Engl J Med
|
2004
|
27.92
|
|
2
|
Supervised risk predictor of breast cancer based on intrinsic subtypes.
|
J Clin Oncol
|
2009
|
22.22
|
|
3
|
Genome remodelling in a basal-like breast cancer metastasis and xenograft.
|
Nature
|
2010
|
19.68
|
|
4
|
The molecular portraits of breast tumors are conserved across microarray platforms.
|
BMC Genomics
|
2006
|
12.45
|
|
5
|
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
|
J Natl Cancer Inst
|
2009
|
10.91
|
|
6
|
HER2 and response to paclitaxel in node-positive breast cancer.
|
N Engl J Med
|
2007
|
9.34
|
|
7
|
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
|
N Engl J Med
|
2015
|
5.57
|
|
8
|
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.
|
Clin Cancer Res
|
2006
|
4.95
|
|
9
|
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
|
Cancer Discov
|
2012
|
4.72
|
|
10
|
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
|
Clin Cancer Res
|
2010
|
4.61
|
|
11
|
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
|
Cell Rep
|
2013
|
3.85
|
|
12
|
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
|
J Clin Oncol
|
2005
|
3.62
|
|
13
|
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
|
J Clin Oncol
|
2013
|
3.24
|
|
14
|
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
|
J Clin Oncol
|
2010
|
3.02
|
|
15
|
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
|
J Clin Oncol
|
2005
|
2.77
|
|
16
|
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
|
Lancet Oncol
|
2013
|
2.47
|
|
17
|
Practical implications of gene-expression-based assays for breast oncologists.
|
Nat Rev Clin Oncol
|
2011
|
2.38
|
|
18
|
Predicting endocrine therapy responsiveness in breast cancer.
|
Oncology (Williston Park)
|
2009
|
2.28
|
|
19
|
The Cancer Genome Atlas: clinical applications for breast cancer.
|
Oncology (Williston Park)
|
2013
|
2.19
|
|
20
|
US breast cancer mortality trends in young women according to race.
|
Cancer
|
2014
|
2.07
|
|
21
|
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
|
BMC Med Genomics
|
2012
|
2.01
|
|
22
|
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
|
Cancer Res
|
2009
|
2.01
|
|
23
|
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
|
Clin Cancer Res
|
2009
|
1.79
|
|
24
|
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
|
J Clin Oncol
|
2009
|
1.64
|
|
25
|
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
|
Cancer Biol Ther
|
2004
|
1.63
|
|
26
|
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
|
Breast Cancer Res
|
2011
|
1.56
|
|
27
|
Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent.
|
Transplantation
|
2013
|
1.54
|
|
28
|
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
|
Clin Cancer Res
|
2012
|
1.52
|
|
29
|
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
|
Breast Cancer Res Treat
|
2006
|
1.51
|
|
30
|
Peripheral lung function in patients with stable and unstable asthma.
|
J Allergy Clin Immunol
|
2013
|
1.50
|
|
31
|
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
|
J Clin Invest
|
2012
|
1.49
|
|
32
|
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
|
Clin Cancer Res
|
2012
|
1.47
|
|
33
|
Clinical implementation of the intrinsic subtypes of breast cancer.
|
Lancet Oncol
|
2010
|
1.47
|
|
34
|
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
|
J Am Coll Surg
|
2009
|
1.46
|
|
35
|
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
|
Breast Cancer Res Treat
|
2009
|
1.46
|
|
36
|
Outcomes in kidney transplant recipients from older living donors.
|
Transplantation
|
2015
|
1.42
|
|
37
|
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
|
Proc Natl Acad Sci U S A
|
2009
|
1.42
|
|
38
|
Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study.
|
Breast Cancer Res Treat
|
2009
|
1.28
|
|
39
|
Molecular basis of triple negative breast cancer and implications for therapy.
|
Int J Breast Cancer
|
2011
|
1.19
|
|
40
|
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
|
J Clin Oncol
|
2010
|
1.17
|
|
41
|
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
|
Breast Cancer Res Treat
|
2013
|
1.10
|
|
42
|
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
|
Breast Cancer Res Treat
|
2012
|
1.10
|
|
43
|
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
|
Breast Cancer Res Treat
|
2011
|
1.10
|
|
44
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2012
|
1.05
|
|
45
|
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
|
Mol Cancer Ther
|
2013
|
1.02
|
|
46
|
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
|
Cancer Chemother Pharmacol
|
2010
|
1.01
|
|
47
|
Neoadjuvant endocrine therapy for locally advanced breast cancer.
|
Semin Oncol
|
2006
|
1.01
|
|
48
|
A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.00
|
|
49
|
Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.
|
J Clin Invest
|
2014
|
1.00
|
|
50
|
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.99
|
|
51
|
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
|
Breast Cancer Res
|
2005
|
0.98
|
|
52
|
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
|
Clin Cancer Res
|
2011
|
0.95
|
|
53
|
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.
|
Mol Endocrinol
|
2014
|
0.94
|
|
54
|
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
|
Clin Cancer Res
|
2011
|
0.94
|
|
55
|
Racial differences in outcomes of triple-negative breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.93
|
|
56
|
Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine.
|
Breast J
|
2004
|
0.90
|
|
57
|
Successful targeting of ErbB2 receptors-is PTEN the key?
|
Cancer Cell
|
2004
|
0.89
|
|
58
|
Molecular pathways: extracting medical knowledge from high-throughput genomic data.
|
Clin Cancer Res
|
2013
|
0.88
|
|
59
|
Molecular profiling of triple negative breast cancer.
|
Breast Dis
|
2010
|
0.88
|
|
60
|
Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
|
J Clin Oncol
|
2005
|
0.87
|
|
61
|
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data.
|
PLoS One
|
2013
|
0.86
|
|
62
|
Incorporating genomics into breast cancer clinical trials and care.
|
Clin Cancer Res
|
2013
|
0.85
|
|
63
|
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.
|
Steroids
|
2011
|
0.84
|
|
64
|
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
|
Cancer Chemother Pharmacol
|
2008
|
0.84
|
|
65
|
A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard.
|
Mod Pathol
|
2013
|
0.83
|
|
66
|
Automated detection of the phase III slope during inert gas washout testing.
|
J Appl Physiol (1985)
|
2011
|
0.81
|
|
67
|
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
|
Clin Cancer Res
|
2004
|
0.81
|
|
68
|
DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gamma.
|
J Med Chem
|
2005
|
0.81
|
|
69
|
ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.
|
Cancer Discov
|
2011
|
0.79
|
|
70
|
Systolic contraction within aneurysmal rabbit myocardium following transplantation of autologous skeletal myoblasts.
|
J Surg Res
|
2006
|
0.79
|
|
71
|
Bronchiolitis obliterans syndrome leads to a functional deterioration of the acinus post lung transplant.
|
Thorax
|
2013
|
0.79
|
|
72
|
New concepts in breast cancer genomics and genetics.
|
Breast Cancer Res
|
2014
|
0.79
|
|
73
|
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.
|
J Oncol
|
2013
|
0.79
|
|
74
|
Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone.
|
Clin Transplant
|
2014
|
0.79
|
|
75
|
Detailed characterization of a long-term rodent model of critical illness and recovery.
|
Crit Care Med
|
2015
|
0.79
|
|
76
|
Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
|
J Natl Cancer Inst
|
2008
|
0.79
|
|
77
|
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
|
Breast Cancer Res Treat
|
2015
|
0.78
|
|
78
|
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
|
Breast Cancer Res
|
2013
|
0.78
|
|
79
|
Hematopoietic stem-cell transplantation.
|
N Engl J Med
|
2006
|
0.77
|
|
80
|
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
|
Clin Cancer Res
|
2004
|
0.77
|
|
81
|
Functional analysis of the breast cancer genome.
|
J Clin Oncol
|
2006
|
0.77
|
|
82
|
"PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy!
|
Clin Cancer Res
|
2007
|
0.77
|
|
83
|
Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer.
|
Breast Cancer Res
|
2010
|
0.77
|
|
84
|
Understanding the estrogen receptor-positive breast cancer genome: not even the end of the beginning.
|
J Natl Cancer Inst
|
2011
|
0.75
|
|
85
|
The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.
|
Oncology (Williston Park)
|
2012
|
0.75
|
|
86
|
Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.
|
Nat Commun
|
2017
|
0.75
|
|
87
|
Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma.
|
Arch Pathol Lab Med
|
2014
|
0.75
|
|
88
|
Neoadjuvant endocrine therapy for breast cancer.
|
Surg Oncol Clin N Am
|
2010
|
0.75
|
|
89
|
Quality Assessments of Long-term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.
|
J Proteome Res
|
2017
|
0.75
|
|
90
|
Letrozole in the treatment of breast cancer.
|
Expert Opin Pharmacother
|
2002
|
0.75
|
|
91
|
Role of biologic markers in patient selection and application to disease prevention.
|
Am J Clin Oncol
|
2003
|
0.75
|
|
92
|
Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
|
Oncology (Williston Park)
|
2004
|
0.75
|
|
93
|
[Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer].
|
Gan To Kagaku Ryoho
|
2009
|
0.75
|